Kornimate/medical-research-clean huggingface dataset:
fish oil brain delivery study

Conditions: Brain Health

Summary: docosahexaenoic acid (dha) is an essential omega-3 fish oil. dha is critical to the structure and function of brain cells. dha fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. it is not known how much dietary fish oil can get into the human brain. thus, exploring fish oil delivery in human brains is critical for designing appropriate interventions.

* the investigators goal is to study how different people deliver dha to the brain. * the study will only require two visits six months apart and involve taking dha during these 6 months. * participants will receive dha supplements for the study duration and a compensation for each study visit. * blood and cerebrospinal fluid levels of dha will be measured before and after taking dha. * brain imaging by mri will be obtained at baseline and at conclusion of study * this study will help us learn how much of the ingested dha goes to the brain.

Eligibility criteria:
inclusion criteria: * ages 55 and above * at risk of alzheimer's disease such as family history of dementia * women have to be postmenopausal exclusion criteria: 1. current smokers (or a recent history of smoking within less than 5 years), 2. having a history of cardiovascular disease defined by a prior heart attack, coronary bypass or percutaneous luminal angioplasty, kidney failure or blindness. 3. a diagnosis of cancer in the past 6 months, uncontrolled hyper- or hypothyroidism 4. taking anti-coagulants such as warfarin 5. anyone consuming n-3 pufa capsules for the last 3 months. 6. regular exercisers (\>5 x30min of aerobic exercise per week), 7. heavy drinkers (\>30 units of alcohol per week). one unit of alcohol is about equal to: half a pint of ordinary strength beer, lager or cider (3-4% alcohol by volume); or. a small pub measure (25 ml) of spirits (40% alcohol by volume); or. a standard pub measure (50 ml) of fortified wine such as sherry or port (20% alcohol by volume) 8. if participants have scores that lie 2 sd outside the means of the neuropsychiatry tests administered, they will have mild cognitive impairment. participant's with mild cognitive impairment are excluded from this study.

Keywords: alzheimer's disease docosahexaenoic acid brain health memory fish oil cognition dha omega 3 fatty acid brain
prevalence of creatinine phosphokinase increase in patients with solid tumors treated by inhibitors of tyrosine kinases

Conditions: Cancer; Solid Tumor

Summary: this study describes the elevation of cpk in patient treated for solid tumors by tki


Eligibility criteria:
inclusion criteria: * patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week * patient examined and with a routine blood test planned * patient informed of procedure for the study who was not opposed to it exclusion criteria: * patient treated for malignant hemopathy * patient no treated by inhibitor of thyrosine kinase or for less than 1 week * patients with no routine blood laboratory tests planned

Keywords: thyrosine kinase inhibitor phosphokinase creatinin myalgia
a prospective cohort study on familial hypercholesterolemia in health examination population

Conditions: Familial Hypercholesterolemia

Summary: to determine the prevalence and the prognosis in a corhort of patients with familial hypercholesterolemia (fh).

this study aims to achieve the following goals through prospective cohort study and statistical analysis: (1) to determine the prevalence of familial hypercholesterolemia (fh) in healthy people with hypercholesterolemia.（2) compared with non fh population, the relative risk of atherosclerotic cardiovascular disease (ascvd) in fh patients in china was calculated, and the risk prediction model of ascvd in fh patients was constructed by using biochemical results, imaging data, biomarkers and other indicators.（3) to evaluate the benefits of different lipid-lowering strategies for fh patients in china.（4) to analyze the gene carriers of fh patients in china.

Eligibility criteria:
inclusion criteria: 1) patients with definite diagnosis of hyperlipidemia. exclusion criteria: 1. age \< 18. 2. do not agree to participate in this study. 3. secondary hypercholesterolemia. 4. phytosteronemia.

Keywords: familial hypercholesterolemia prognosis
myocardial regeneration and angiogenesis in myocardial infarction with g-csf and intra-coronary stem cell infusion-3-des

Conditions: Myocardial Infarction

Summary: this trial was performed to evaluate the safety of g-csf based stem cell therapy and to compare outcome of intracoronary infusion of mobilized pbscs between patients with ami and omi.

the magic cell-des trial was designed as a randomized, controlled trial to recruit 100 patients with ami and omi. patients who were successfully revascularized with des in the culprit lesion were eligible for enrollment. after revascularization, patients were randomized by use of a randomization table. after randomization, study processes were not blinded. in the cell infusion groups after successful pci, pbscs were mobilized by daily subcutaneous injections of g-csf (dong-a pharmaceutical, seoul, korea) at 10 g/kg body weight for three days. at day 4, mobilized pbscs were collected with cobe spectra apheresis system (cobe bct. inc., lakewood, co, usa) using the mononuclear cell collection methods and infused selectively to infarcted myocardium via over-the-wire balloon catheter. the primary end point to evaluate efficacy was the change in lvef, measured by mri. the secondary end points were changes in lv volume, myocardial perfusion measured by coronary flow reserve (cfr), and the development of major adverse cardiac events (mace; death, new mi, revascularization, hospitalization due to aggravation of ischemia or heart failure).

Eligibility criteria:
inclusion criteria: * patients with acute or old myocardial infarction who were successfully revascularized with des in the culprit lesion were eligible for enrollment. exclusion criteria: * 1) persistent severe heart failure (left ventricular ejection fraction (lvef) \ 80 years 5) malignancy 6) serious current infection or hematologic disease; and 7) life expectancy under one year.

Keywords: myocardial infarction revascularization drug eluting stents
obesity intervention program for university students

Conditions: Obesity

Summary: the aim of this study is to determine the effect of preventive nursing interventions, which consist of education / practices including of healthy eating and physical activity and motivational messages which sent through social media to reduce obesity risk in university students who in the risk group for obesity.

this study has been conducted with university students in turkey. the selected 70 students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental (35 students) and control group (35 students). applications for the experimental group for 11 weeks about nutritional habits, practices for physical activity, and motivational messages sent via social media. primary outcome measure: nutrition-exercise attitude score, nutrition-exercise behavior score, exercise benefit / obstacle score. we used some scales for evaluate the primary outcomes (the scale of nutrition-exercise attitude-behavior, the scale of exercise benefit / obstacle). bady mass index, waist / hip ratio and body fat percentage are secondary outcomes. the data was calculated with spss package program.

Eligibility criteria:
inclusion criteria: * preobezes between 25.0-29.9 bmi * the bmi is 18.5-24.9 and who get above the average score (24-36 points high risk) from the "risky behavior scale university form: the subscale of nutritional habits * the bmi is 18.5-24.9 and who get below the mean score (8-20 points high risk) from the healthy lifestyle behavior scale's subscale of exercise exclusion criteria: * bmi below 18.5 and above 29.9 * constantly regular drug users * those who have any health problems (who have had a heart attack, angioplasty or any surgical operation within 3 months, those with heart failure, those with metabolic disease, those with eating disorder, those with cancer, those with any psychological disease, physically disabled) * those who are pregnant * those who have participated in any weight management program at least 2 months in advance and are still involved in the nutrition or physical activity program

Keywords: obesity overweight physical activity nutrition nursing
safety and efficacy of biphasic insulin aspart 50 in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in japan. the aim of this trial is to investigate the safety and efficacy of biphasic insulin aspart (biasp) 50 (nn-x14mix50) compared with biphasic human insulin (bhi) 50 in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes * subjects with insulin treated for at least 24 weeks * hba1c maximum 11.0% * body mass index (bmi) below 30.0 kg/m\^2 * patients who have the skill of self-injection of insulin, and are able and willing to perform self-monitoring blood glucose (smbg) and are able to take measures against hypoglycaemic episodes exclusion criteria: * recurrent severe hypoglycaemia * subjects with proliferative retinopathy or preproliferative retinopathy diagnosed within the last 12 weeks, or receiving photocoagulation therapy within the last one year * impaired hepatic function * impaired renal function * cardiac diseases * uncontrolled hypertension * subjects with history of severe allergic or severe hypersensitive reactions * total daily insulin dose at least 100 iu * treatment with oral hypoglycaemic agentsvwithin the last 4 weeks
phosphatidylcholine (lt-02) vs. placebo vs. mesalamine for maintenance of remission in ulcerative colitis (protect-2)

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (lt-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (uc)


Eligibility criteria:
major inclusion criteria: * signed informed consent * men or women, 18 to 70 years of age * historically confirmed diagnosis of uc by endoscopy and histology * patients being in clinical and endoscopical remission at baseline * negative pregnancy test in females of childbearing potential at baseline visit major exclusion criteria: * crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis * toxic megacolon or fulminant colitis * colon resection * malabsorption syndromes * celiac disease * bleeding hemorrhoids * other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding * history or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack * any severe concomitant renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results * any relevant known systemic disease (e.g., aids, active tuberculosis) * severe co-morbidity substantially reducing life expectancy * history of cancer in the last five years * abnormal hepatic function at screening visit, liver cirrhosis * abnormal renal function at screening visit * patients with known hypersensitivity to soy * known intolerance/hypersensitivity to investigational medicinal product (imp: lt-02 or mesalamine) * treatment with steroids (oral, inhalative, or intravenous \[iv\]), cyclosporine or tacrolimus within last 4 weeks prior to randomization * treatment with methotrexate within last 6 weeks prior to randomization * treatment with tnf-alpha-antagonists, azathioprine, 6-mercaptopurine, or anti-integrin therapy within last 8 weeks prior to randomization * treatment with rectal mesalamine or corticosteroid formulations within last 2 weeks prior to randomization * treatment with other investigational drug within last 12 weeks prior to randomization except lt-02 * existing or intended pregnancy or breast-feeding
efficacy and safety of the lovenoxtm (enoxaparin) versus heparintm gynecologic oncology patients

Conditions: Malignant Female Reproductive System Neoplasm

Summary: prophylactic treatment will start from surgery until the patients are discharged from the hospital(18). then each patient will have 2 follow up visit in gyne- oncology clinic. the first visit will be 2 weeks from discharge \& the second visit will be 3 months after surgery. in each visit patient will be evaluated for any evidence of thrombo-embolic events clinically \& radiologically if needed ( spiral ct, v/q scan \& lower limp doppler ). any side effect or adverse reaction will be reported \& it will be evaluated if it is related to the drug used or not.

this study is a phase iiib, randomized, open label, non-comparative controlled trial, and prospectively enrolling 150 females to assess the efficacy and safety of the enoxaparin (group a) and unfractionated heparin (group b) for gynecologic oncology patients in the kingdom of saudi arabia who required surgery or admission for the prevention of vte. patients who meet the inclusion criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (group a or group b). subjects will be assigned consecutive study numbers according to a predetermined random code generated by the biostatistician. the randomisation will be based on a 1:1 ratio.

Eligibility criteria:
inclusion criteria: 1. cancer patients aged 18 years or older were admitted with diagnosis of malignancy or suspension of malignancy and going for major surgery. 2. patient with the following conditions: 1. any patient were admitted with diagnosis of gynecologic malignancy \& going for major surgery such as laparotomies \& abdominal hysterectomy or 2. all staging laparotomies done for suspected ovarian malignancy by either ultrasound finding or tumor markers (raised ca 125) \& found to be either borderline or benign ovarian tumor 3. signed the informed consent form exclusion criteria: 1 renal failure assessed by serum creatinine \> 2.0mg/dl (180 mmol/l) 2. patients on anticoagulant treatment in the previous 6 months 3. bleeding disorders or platelet count \< 80x109/l 4. known hypersensitivity to unfractionated heparin or lmwhs 5. pregnant women 6. obese patients with body mass index ≥ 47

Keywords: gynecologic malignancy ,major surgery
assessment of a tool for decision making in case of worsening condition of cancer patients

Conditions: Lung Cancer

Summary: observational two year study to evaluate the utility of a decision-support sheet on how to proceed in case of aggravation of a patient's condition with advanced disease.

prospective and multicenter study conducted in the rhône-alpes-auvergne area. all patients suffering from lung cancer admitted to a pulmonology unit in 2014 will be included. this document will be used if a decision to withhold life-sustaining treatment is decided. investigators will assess the relationship between the planned intensity of care and those established when the patient develops an organ failure. patient characteristics and factors associated with proposed levels and types of care will be analyzed. patient and family opinions will be obtained after 3 months. the number of subjects is 468.

Eligibility criteria:
inclusion criteria: * any patient with lung cancer, hospitalized in pulmonology unit in one of the participating centers. * patient who requires a decision to withhold life-sustaining treatment * one patient can be included at each hospitalization. exclusion criteria: * minor patient * refusal of participation of the patient in the study

Keywords: decision-support sheet
malnutrition in people with complex multiple disabilities

Conditions: Complex Multiple Disabilities; Malnutrition

Summary: underweight is more prevalent in people with a mental handicap than in people without a mental handicap, especially in people with a severe mental handicap. it is unknown if these people are malnourished. there is no validated screening instrument available to determine the nutrition status in people with complex multiple disabilities. research regarding malnutrition based on body composition and nutrients in stead of anthropometric data is important. the aim of the study is to understand the nutritional status of people with complex multiple disabilitiest through measurement of body composition and nutritients. the primary objective of the study is: what percentage of people with complex multiple disabilities are malnourished, based on altered body composition and nutritients? understanding the nutritional status of these patients is important in order for them to receive appropriate and effective treatment. this treatment is of interest for general health and the quality of daily life.


Eligibility criteria:
inclusion criteria: * person with complex multiple disabilities; * living in a care institution participating in the governor kremers centre (gkc); * chronically confined to a wheelchair or bedridden; * 18+ years exclusion criteria: * parenteral nutrition; * serious infection; * terminal illness

Keywords: complex multiple disabilities malnutrition
dsme or dsme + mi in t1dm on glycemic control

Conditions: Diabetes Mellitus

Summary: this study evaluates the effect of diabetic knowledge and self care behavior (dsme) alone or dsme plus motivational interviewing on glycemic control among children and adolescents with dm type 1. half of participants will receive dsme along, while the other half will receive dsme plus mi.


Eligibility criteria:
inclusion criteria: * t1dm * age more than 10 years old * hba1c more than 8% exclusion criteria: * other types of dm * receive medications that may effect blood glucose * mental retardation
the effectiveness of sensawake™ for continue positive airway pressure treatment of obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: this study will investigate obstructive sleep apnea (osa) and an automatically adjusting positive airway pressure (apap) device with new technology called sensawake™. this requires experimental confirmation in a randomised controlled trial with crossover design, comparing compliance on standard apap with compliance using apap modified by the addition of the sensawake™ modification on consecutive nights in participants with moderate-to-severe osa.


Eligibility criteria:
inclusion criteria: 1. participants will be recruited from osa patients who will remove cpap himself without any notable reasons. exclusion criteria: 1. unstable cardiovascular disease (untreated or resistant hypertension acceptable). 2. inability to tolerate cpap due to nasal obstruction or claustrophobia as determined by the study investigator. 3. any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements. 4. any known factor that result in mask taken of such as skin discomfort, nasal obstruction, water dripping inside the tubing system etc.

Keywords: cpap senseawake
rtms for relieving chronic oa pain

Conditions: Chronic Pain; Osteo Arthritis Knee

Summary: in this study the investigators aim to examine the effects of transcranial magnetic stimulation (tms) on hippocampal network connectivity and pain levels in individuals with pain due to knee osteoarthritis.

osteoarthritis (oa) pain is one of the most prevalent causes of chronic pain worldwide. symptoms can last from months to a lifetime, severely impacting patients' quality of life. new strategies - including non-invasive brain stimulation techniques - have shown promise for sustained pain relief, yet evidence on their reliability and efficacy is limited. apkarian et. al have previously shown that the dorsal hippocampus plays a central role in pain analgesia; thus, the study aim is to test whether non-invasively enhancing dorsal hippocampus activity is a useful new strategy for pain relief in knee oa patients. this study will recruit 35 patients with chronic oa pain for \> 6 months. each participant will receive 3 rounds of different treatment modalities in a cross-over manner. each treatment modality will consist of 5 daily consecutive rtms sessions followed by a 2-weeks wash-out period. questionnaires will be completed prior to and following each intervention, and after each treatment round. participants will be trained to use a pain electronic application (smartphone-based tool to rate pain intensity and mood on nrs scales, as well as indicate rescue medication use, developed in our lab). they will be asked to use this application for 7-10 days prior to the first round of intervention and during the study duration.

Eligibility criteria:
inclusion criteria: * ≥ 6 months of knee pain on a daily basis; * male or female with no racial or ethnic restrictions; * 18 to 75 years old; * average knee pain intensity \> 4/10 at study entry; * must be able to read, understand, and sign consent form; * generally healthy. * able to use the painapp exclusion criteria: * rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures, * chronic neurologic conditions, e.g., parkinson's * other severe medical diseases; * pregnancy; * positive urinary screen for any recreational drugs, * opioids use; * use of anticoagulants (low dose asa allowed); * history of gastric ulcer; renal insufficiency or congestive heart failure, * contraindication to mri, * contraindication to tms; including history of seizure/epilepsy\* * any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk; * in the judgment of the investigator, unable or unwilling to follow protocol and instructions. * diagnosis of major depression.